INDO抗体;INDO Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of INDO expression in HeLa cell lysate treated with IFN gamma.    

  
  

**Background of INDO Antibody**

The INDO antibody targets indoleamine 2.3-dioxygenase (IDO), a heme-containing enzyme that catalyzes the rate-limiting step in tryptophan metabolism via the kynurenine pathway. IDO is widely recognized for its immunosuppressive role, particularly in the tumor microenvironment and inflammatory conditions. By degrading tryptophan and producing kynurenine metabolites, IDO suppresses T-cell activation and promotes regulatory T-cell differentiation, enabling immune tolerance. This mechanism is exploited by cancers and pathogens to evade host immune responses.

INDO antibodies are essential tools in studying IDO expression and function, aiding in diagnostics and research on diseases like cancer, autoimmune disorders, and chronic infections. In cancer research, IDO overexpression correlates with poor prognosis, making it a therapeutic target. Antibodies against IDO are used in immunohistochemistry, flow cytometry, and Western blotting to assess its expression in tissues or cells. Additionally, therapeutic strategies using IDO inhibitors or blocking antibodies aim to counteract immunosuppression, often in combination with checkpoint inhibitors (e.g., anti-PD-1/PD-L1).

Despite promising preclinical results, clinical trials targeting IDO have shown mixed outcomes, highlighting the complexity of its role in immune regulation. Nonetheless, INDO antibodies remain crucial for unraveling IDO's biological impact and advancing immunotherapeutic approaches.